Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330239 · ClinicalTrials.gov registry record · Phase 4
Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence
A Phase 4 study of PTSD, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00330239 is a Phase 4 study of PTSD that has completed, run by Medical University of South Carolina. The registered enrollment target is 25 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00330239, a Phase 4 study of PTSD, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Pharmacotherapy has demonstrated efficacy in a number of controlled trials in the treatment of PTSD. The selective serotonin reuptake inhibitors have proven particularly useful in treating this disorder. Currently there are two selective serotonin reuptake inhibitors (Zoloft® and Paxil®), that have been FDA approved for treating PTSD. Coincidentally, this same class of medications has also been shown to have efficacy in some trials in decreasing alcohol consumption in heavy drinkers. The goal of the proposed study is to preliminarily investigate the efficacy of Paxil® (paroxetine), in decreasing symptoms of PTSD as well as decreasing substance use, in individuals with concurrent substance dependence and PTSD. The type of paroxetine used in this trial will be Paxil CR®, which is a sustained release formulation of paroxetine, which has fewer side effects and greater tolerability. This is a particularly important issue in substance using populations because medication compliance is generally poor. Two specific hypotheses will be tested. 1) Individuals who receive Paxil CR® will have a greater improvement in their PTSD symptoms (based on CAPS-2 and CGI) than those who receive placebo. 2) Individuals who receive Paxil CR® will have greater improvement in their substance use outcomes (based on UDS and TLFB) than will those who receive placebo.
Conditions Studied
Interventions
- DRUG Paroxetine CR
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330239
The ClinicalTrials.gov registry entry for NCT00330239 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (92% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which Paroxetine CR is the first listed.
NCT00330239 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT00330239 about?
NCT00330239 is a clinical study titled "Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence". Pharmacotherapy has demonstrated efficacy in a number of controlled trials in the treatment of PTSD. The selective serotonin reuptake inhibitors have proven particularly useful in treating this disorder. Currently there are two selective serotonin reuptake inhibitors (Zoloft® and Paxil®), that have ...
What is the current status of trial NCT00330239?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2003-01. Estimated completion is 2005-05.
What conditions does trial NCT00330239 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT00330239?
The interventions under investigation include: Paroxetine CR (DRUG).
Who is sponsoring clinical trial NCT00330239?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00330239 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD
RECRUITING · Phase 4
-
Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)
COMPLETED · Phase 4
-
Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder
COMPLETED · Phase 4
-
Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans
COMPLETED · Phase 4
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.